Kevzara is an injectable fully human monoclonal antibody directed against the interleukin-6 (IL-6) receptor for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response or are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs). Proinflammatory cytokines such as IL-6 are linked to the disease process in RA and play a critical role in joint destruction; the IL-6 receptor has been identified as a potential target for RA therapies.

If you have a Hayes login, click here to view the full report on the Knowledge Center.